This site is intended for healthcare professionals
Latest industry news
  • Home
  • /
  • News
  • /
  • 2014
  • /
  • 06
  • /
  • Merck Inc. to acquire Idenix Pharma for $3.85 bill...
Industry news

Merck Inc. to acquire Idenix Pharma for $3.85 billion and with it Hepatitis C drug developments

Read time: 1 mins
Last updated:10th Jun 2014
Published:10th Jun 2014
Source: Pharmawand

Merck Inc., and Idenix Pharmaceuticals, Inc. have announced that the companies have entered into a definitive agreement under which Merck will acquire Idenix for $24.50 per share in cash. The transaction, which values the purchase of Idenix at approximately $3.85 billion, has been approved by the boards of directors of both companies. Idenix has established a promising portfolio of Hepatitis C candidates based on its expertise in nucleoside/nucleotide chemistry and prodrug technologies. These investigational Hepatitis C candidates complement developing therapies at Merck and will help advance the work of Merck to develop a highly effective, once-daily, all oral, ribavirin-free, pan-genotypic regimen that has a duration of treatment as short as possible for millions of patients in need around the world. Idenix currently has three HCV drug candidates in clinical development: two nucleotide prodrugs (IDX 21437 and IDX 21459) and a NS5A inhibitor (samatasvir).

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.